Isl1+ Cell Derivation Using Laminin and Wnt Pathway Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for efficiently deriving and expanding multipotent Isl1+ cells, which are essential for cardiac tissue repair due to low cardiomyocyte turnover in adult hearts and insufficient upregulation of endogenous progenitor cells during ischemia, leading to heart failure.
Innovation Solution
Culturing mesenchymal stem cells in the presence of laminin with an α5 chain and a medium activating the Wnt canonical pathway to derive and maintain Isl1+ cells, allowing for their self-renewal and differentiation into cardiac cells, such as cardiomyocytes, smooth muscle cells, and endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mesenchymal stem cells are cultured using conventional methods, then cell expansion is limited, but the complexity of culture conditions and reagents is reduced
Solution Approach 1:
The invention changes the chemical composition parameters of the culture medium by specifying exact concentrations of growth factors (bFGF at 2-20 ng/mL, EGF at 2-20 ng/mL, FGF-2 at 2-20 ng/mL) and extracellular matrix components (laminin at 1-10 μg/mL, fibronectin at 1-10 μg/mL), transforming conventional undefined culture conditions into a precisely controlled formulation that enables indefinite expansion of Isl1+ cells while maintaining their multipotent state
Solution Approach 2:
The invention introduces extracellular matrix components (laminin and fibronectin) as intermediary substances that mediate between the culture medium and mesenchymal stem cells, providing critical adhesion and signaling functions that enable sustained cell expansion and maintenance of progenitor characteristics without requiring complex feeder cell systems
2Reliability
If endogenous progenitor cells are upregulated during ischemia, then some tissue repair occurs, but the repair is insufficient to replace damaged musculature and prevent heart failure
Solution Approach 1:
The invention performs preliminary action by expanding Isl1+ progenitor cells ex vivo under optimized culture conditions before transplantation, generating large quantities of characterized multipotent cells that can be stored and administered as needed, rather than relying solely on the insufficient endogenous upregulation that occurs naturally during ischemic events
Solution Approach 2:
The invention enables self-service by deriving Isl1+ cells from the patient's own mesenchymal stem cells (autologous source), allowing the cells to self-renew indefinitely in culture and differentiate into cardiac lineages after transplantation, providing a self-sustaining regenerative solution without requiring external feeder cells or complex support systems
Data Source
AI summary
The present invention relates to methods for deriving multipotent Isl1+ cells (i.e. methods for inducing a cell to enter a multipotent Isl1+ lineage), methods for differentiating Isl1+ cells to cardiac cells, cells obtainable by such methods, kits and compositions for carrying out the methods in accordance with the invention, and also medical applications and pharmaceutical compositions of said cells.